The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2020 | Chemo-IO, IO-IO, or IO-mono: which is correct for lung cancer?

Name: Chemo-IO, IO-IO, or IO-mono: which is correct for lung cancer?
Uploaded: 2020-01-31T00:00:00Z
Duration: 3 min 15 s
Description: Benjamin Besse, MD, PhD, Institut Gustave Roussy, Villejuif, France, discusses in which cases chemotherapy in combination with immunotherapy, immunotherapy alone, or a combination of immunotherapies are correct. Dr Besse believes each approach can benefit different subsets of patients. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

Benjamin Besse • 31 Jan 2020

BTOG 2020

Lung Cancer Non-Small Cell Lung Cancer

Benjamin Besse, MD, PhD, Institut Gustave Roussy, Villejuif, France, discusses in which cases chemotherapy in combination with immunotherapy, immunotherapy alone, or a combination of immunotherapies are correct. Dr Besse believes each approach can benefit different subsets of patients. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.